Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions

• Leukemia
• Myeloid
• Acute
• Newly Diagnosed

Interventions

• DRUG: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1
• DRUG: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A
• DRUG: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax
• DRUG: MP0533 with Obinutuzumab pretreatment
• DRUG: MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML
• DRUG: MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients

Sponsor

Molecular Partners AG